Stock Events

Stock Events

Zafgen 

0
35
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q1 2026
Next
-0.46
-0.39
-0.33
-0.27
Expected EPS
-0.33544477728000005
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-143.19MNet Income

Analyst Ratings

8.54Average Price Target
The highest estimate is 10.62.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ZA7.STU. It's not an investment recommendation.
Apple
9
AAPL
Amazon
9
AMZN
Microsoft
8
MSFT
NVIDIA
8
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for rare diseases, similar to Larimar's focus on genetic disorders.
PTC Therapeutics
PTCT
Mkt Cap7.04B
PTC Therapeutics operates in the field of genetic disorders, particularly targeting Duchenne muscular dystrophy and cystic fibrosis, overlapping with Larimar's therapeutic areas.
Solid Biosciences
SLDB
Mkt Cap956.93M
Solid Biosciences is involved in developing therapies for Duchenne muscular dystrophy, a key area of focus for Larimar Therapeutics.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.43B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for rare diseases and medical conditions, competing in the same space as Larimar.
Ultragenyx Pharmaceutical
RARE
Mkt Cap3.33B
Ultragenyx Pharmaceutical focuses on rare and ultra-rare diseases, directly competing with Larimar in the niche market of genetic disorders.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics is engaged in the development of gene-based therapies, which could potentially address the same genetic disorders as Larimar's treatments.
Editas Medicine
EDIT
Mkt Cap500.29M
Editas Medicine works on editing genes to treat genetic diseases, posing a direct competition to Larimar's gene therapy approach.
Intellia Therapeutics
NTLA
Mkt Cap1.99B
Intellia Therapeutics is a leading company in gene editing for the treatment of genetic diseases, competing in the same innovative space as Larimar.
uniQure N.V.
QURE
Mkt Cap2.93B
uniQure is known for its work in gene therapy targeting hemophilia, but its platform could be adapted to compete with Larimar's focus areas.

About

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Show more...
CEO
Dr. Carole S. Ben-Maimon M.D.
Employees
71
Country
United States
ISIN
US98885E1038

Listings

STU
DE
ZA71.STU
STU
DE
ZA7.STU
XNAS
US
LRMR
F
DE
ZA71.F

0 Comments

Share your thoughts

FAQ

What is Zafgen stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Zafgen stocks are traded under the ticker ZA7.STU.
When is the next Zafgen earnings date?▼
Zafgen is going to release the next earnings report on August 06, 2026.
What were Zafgen earnings last quarter?▼
ZA7.STU earnings for the last quarter are -0.27 EUR per share, whereas the estimation was -0.46 EUR resulting in a +42.01% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Zafgen revenue for the last year?▼
Zafgen revenue for the last year amounts to 0 EUR.
What is Zafgen net income for the last year?▼
ZA7.STU net income for the last year is -143.19M EUR.
How many employees does Zafgen have?▼
As of July 25, 2026, the company has 71 employees.
In which sector is Zafgen located?▼
Zafgen operates in the Health & Wellness sector.
When did Zafgen complete a stock split?▼
The last stock split for Zafgen was on May 29, 2020 with a ratio of 1:12.
Where is Zafgen headquartered?▼
Zafgen is headquartered in Bala Cynwyd, United States.